George R. Cowgill Professor of Medicine and Cellular and Molecular Physiology
Yale School of Medicine
New Haven, Connecticut, United States
Dr. Shulman is the George R. Cowgill Professor of Physiological Chemistry, Professor
of Internal Medicine and Cellular & Molecular Physiology at Yale University and an
Investigator Emeritus of the Howard Hughes Medical Institute. He is also Co-Director of
the Yale Diabetes Research Center. Dr. Shulman has pioneered the use of magnetic
resonance spectroscopy combined with stable isotopes and mass spectrometry to
non-invasively examine intracellular glucose andfat metabolism in humans thathave led
to several paradigm shifts in our understanding of type 2 diabetes, including the
molecular mechanisms by which ectopic lipids promote liver and muscle insulin
resistance, as well as developing new drugs for the treatment of type 2 diabetes,
nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Dr. Shulman is the
recipient of the Stanley J. Korsymeyer Award from the American Society for Clinical
Investigation, the Outstanding Clinical Investigator Award from the Endocrine Society, the
Solomon Berson Award from the American Physiological Society and the Banting Medal
for Lifetime Scientific Achievement from the American Diabetes Association. Dr. Shulman
is a Fellow of the American Association for the Advancement of Science, Inaugural
Fellow of the American Physiological Society, Mastership in the American College of
Physicians, Mastership in the American College of Endocrinologists, Fellowship in the
Royal College of Physicians (London) and he has been elected to the American Society
for Clinical Investigation, the Association of American Physicians, the National
Academy of Medicine, the American Academy of Arts and Sciences and the National
Academy of Sciences.
Hepatic Ketone Production as the Governing Factor in Determining Fatty Liver and Type 2 Diabetes
Monday, July 1, 2024
10:00 AM – 11:30 AM CT
Disclosure(s): Aro Biotherapeutics: Consultant (Ongoing)
Arrowhead Pharmaceuticals: Speaker/Speaker's Bureau (Terminated, December 18, 2023)
AstraZeneca: Consultant (Terminated); Grant/Research Support (Terminated)
Bayer AG: Consultant (Ongoing)
Betagenon AB: Consultant (Ongoing)
DiCerna Pharmaceuticals, Inc.: Consultant (Ongoing)
Equator Therapeutics: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
Esperion Therapeutics: Consultant (Ongoing)
Eternygen GmbH: Consultant (Terminated, January 1, 2024)
Fortress Biotech: Consultant (Ongoing)
Generian Pharmaceuticals: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
iMetabolic Biopharma Corporation: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
Janssen: Consultant (Terminated, January 1, 2024); Speaker/Speaker's Bureau (Terminated, January 1, 2024)
Kriya Therapeutics,: Consultant (Ongoing)
Levels Health: Stock Shareholder (excluding mutual funds) (Ongoing)
Mammoth BioSciences, Inc: Consultant (Ongoing)
Maze Therapeutics, Inc.: Consultant (Terminated, January 1, 2023); Grant/Research Support (Terminated, January 1, 2023)
Merck Pharmaceuticals: Consultant (Ongoing); Grant/Research Support (Ongoing)
Novo Nordisk: Consultant (Ongoing)
OrsoBio: Stock Shareholder (excluding mutual funds) (Ongoing)
MRS and Mass Spectrometry: Windows into the Inner Workings of Metabolic Disease
Monday, July 1, 2024
10:00 AM – 10:25 AM CT
Disclosure(s): Aro Biotherapeutics: Consultant (Ongoing)
Arrowhead Pharmaceuticals: Speaker/Speaker's Bureau (Terminated, December 18, 2023)
AstraZeneca: Consultant (Terminated); Grant/Research Support (Terminated)
Bayer AG: Consultant (Ongoing)
Betagenon AB: Consultant (Ongoing)
DiCerna Pharmaceuticals, Inc.: Consultant (Ongoing)
Equator Therapeutics: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
Esperion Therapeutics: Consultant (Ongoing)
Eternygen GmbH: Consultant (Terminated, January 1, 2024)
Fortress Biotech: Consultant (Ongoing)
Generian Pharmaceuticals: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
iMetabolic Biopharma Corporation: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
Janssen: Consultant (Terminated, January 1, 2024); Speaker/Speaker's Bureau (Terminated, January 1, 2024)
Kriya Therapeutics,: Consultant (Ongoing)
Levels Health: Stock Shareholder (excluding mutual funds) (Ongoing)
Mammoth BioSciences, Inc: Consultant (Ongoing)
Maze Therapeutics, Inc.: Consultant (Terminated, January 1, 2023); Grant/Research Support (Terminated, January 1, 2023)
Merck Pharmaceuticals: Consultant (Ongoing); Grant/Research Support (Ongoing)
Novo Nordisk: Consultant (Ongoing)
OrsoBio: Stock Shareholder (excluding mutual funds) (Ongoing)
Monday, July 1, 2024
11:15 AM – 11:30 AM CT
Disclosure(s): Aro Biotherapeutics: Consultant (Ongoing)
Arrowhead Pharmaceuticals: Speaker/Speaker's Bureau (Terminated, December 18, 2023)
AstraZeneca: Consultant (Terminated); Grant/Research Support (Terminated)
Bayer AG: Consultant (Ongoing)
Betagenon AB: Consultant (Ongoing)
DiCerna Pharmaceuticals, Inc.: Consultant (Ongoing)
Equator Therapeutics: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
Esperion Therapeutics: Consultant (Ongoing)
Eternygen GmbH: Consultant (Terminated, January 1, 2024)
Fortress Biotech: Consultant (Ongoing)
Generian Pharmaceuticals: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
iMetabolic Biopharma Corporation: Consultant (Ongoing); Stock Shareholder (excluding mutual funds) (Ongoing)
Janssen: Consultant (Terminated, January 1, 2024); Speaker/Speaker's Bureau (Terminated, January 1, 2024)
Kriya Therapeutics,: Consultant (Ongoing)
Levels Health: Stock Shareholder (excluding mutual funds) (Ongoing)
Mammoth BioSciences, Inc: Consultant (Ongoing)
Maze Therapeutics, Inc.: Consultant (Terminated, January 1, 2023); Grant/Research Support (Terminated, January 1, 2023)
Merck Pharmaceuticals: Consultant (Ongoing); Grant/Research Support (Ongoing)
Novo Nordisk: Consultant (Ongoing)
OrsoBio: Stock Shareholder (excluding mutual funds) (Ongoing)